TY-302 is under clinical development by Tetranov International and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II drugs for Prostate Cancer have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TY-302’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TY-302 overview

TY-302 Is under development for the treatment of solid tumors including HR+/HER2- locally advanced metastatic breast cancer, acute myeloid leukemia, ovarian cancer, melanoma, lung cancer, triple-negative breast cancer, head and neck tumors and prostate cancer. The therapeutic candidates are palbociclib derivatives and act by targeting cyclin-dependent kinase 4 and 6 (CDK4/6). It is administered through oral route.

For a complete picture of TY-302’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.